OncLive SOSS

Updates in Advanced Renal Cell Carcinoma from The 2022 International Kidney Cancer Symposium - Episode 3

Updates from the CLEAR Study on Efficacy of Lenvatinib plus Pembrolizumab in Patients with Advanced RCC

December 22, 2022

Hans Hammers, MD, PhD, Moshe Ornstein, MD

Drs Hans Hammers reviews updated efficacy data on the use of lenvatinib plus pembrolizumab for frontline advanced renal cell carcinoma treatment.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Overview of the Frontline Management and Risk Stratification of Advanced Renal Cell Carcinoma (RCC)

EP. 2: Comparing IO/IO and IO/TKI Frontline Treatment in Advanced RCC

EP. 3: Updates from the CLEAR Study on Efficacy of Lenvatinib plus Pembrolizumab in Patients with Advanced RCC

EP. 4: Lenvatinib Dosing Strategies in Frontline Advanced RCC Treatment

EP. 5: Nivolumab plus Ipilimumab for Frontline Treatment of Advanced RCC: 5-Year Follow-Up from the CheckMate 214 Trial

EP. 6: Managing Adverse Events of IO/IO Frontline Combination Therapies in Advanced RCC Treatment

EP. 7: COSMIC-313: Frontline Triplet Therapy in Advanced RCC

EP. 8: Emerging Data in Non-Clear Cell RCC Treatment

EP. 9: Exciting Investigational Therapies in Advanced RCC

x